Literature DB >> 11594668

The evolving role of Propionibacterium acnes in acne.

J J Leyden1.   

Abstract

Propionibacterium acnes is a member of the resident cutaneous flora. Sebaceous follicles involved in acne are characterized by the accumulation of abnormally desquamated corneocytes and excess sebum-the microcomedo. This environment provides ideal growth conditions for P acnes. Several orders of magnitude level of P acnes are found in microcomedos. P acnes produces a variety of chemotactic factors and proinflammatory molecules that are responsible for the inflammatory phase of acne. Antibiotic therapy works by reducing the viable number of P acnes as well as by reducing the production of inflammatory stimuli. Antibiotic therapy has been a mainstay of treatment for more than 30 years. In the last decade, decreased sensitivity to antibiotics has developed and clinical resistance has been described. This development threatens the usefulness of antibiotic therapy in the future.

Entities:  

Mesh:

Year:  2001        PMID: 11594668     DOI: 10.1053/sder.2001.28207

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  16 in total

Review 1.  Acne vulgaris.

Authors:  Guy F Webster
Journal:  BMJ       Date:  2002-08-31

2.  The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin.

Authors:  Jared Liu; Riceley Yan; Qiao Zhong; Sam Ngo; Nathanael J Bangayan; Lin Nguyen; Timothy Lui; Minghsun Liu; Marie C Erfe; Noah Craft; Shuta Tomida; Huiying Li
Journal:  ISME J       Date:  2015-04-07       Impact factor: 10.302

3.  Oral antibiotics in acne vulgaris: therapeutic response over 5 years.

Authors:  J Adawiyah; G Priya; B Roshidah
Journal:  Malays Fam Physician       Date:  2010-12-31

Review 4.  Oral Antibiotics for Acne.

Authors:  Dillon J Patel; Neal Bhatia
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 7.403

5.  Propionibacterium acnes and Staphylococcus epidermidis isolated from refractory endodontic lesions are opportunistic pathogens.

Authors:  Sadia A Niazi; Douglas Clarke; Thuy Do; Steven C Gilbert; Francesco Mannocci; David Beighton
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

Review 6.  Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

7.  Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice.

Authors:  Tetsu Nishiwaki; Hiroyuki Yoneyama; Yoshinobu Eishi; Naoki Matsuo; Koichiro Tatsumi; Hiroshi Kimura; Takayuki Kuriyama; Kouji Matsushima
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris.

Authors:  Teruaki Nakatsuji; Mandy C Kao; Jia-You Fang; Christos C Zouboulis; Liangfang Zhang; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

9.  The protective effects of melittin on Propionibacterium acnes-induced inflammatory responses in vitro and in vivo.

Authors:  Woo-Ram Lee; Kyung-Hyun Kim; Hyun-Jin An; Jung-Yeon Kim; Young-Chae Chang; Hyun Chung; Yoon-Yub Park; Myeong-Lyeol Lee; Kwan-Kyu Park
Journal:  J Invest Dermatol       Date:  2014-02-04       Impact factor: 8.551

10.  Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris.

Authors:  Teruaki Nakatsuji; Yu-Tsueng Liu; Cheng-Po Huang; Christos C Zoubouis; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2008-05-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.